Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Melanoma 68Carcinoma, Non-Small-Cell Lung 41Carcinoma, Renal Cell 36Neoplasm Metastasis 22Carcinoma, Hepatocellular 15Neoplasms 14Colorectal Neoplasms 13Brain Neoplasms 13Skin Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Pancreatic Neoplasms 10Lung Neoplasms 10Kidney Neoplasms 10Uveal Melanoma 9Ovarian Neoplasms 9Urinary Bladder Neoplasms 8Sarcoma 8Prostatic Neoplasms 8Carcinoma, Transitional Cell 8Mesothelioma 7Glioblastoma 7Clear-cell metastatic renal cell carcinoma 7Carcinoma, Merkel Cell 7Recurrence 6Colonic Neoplasms 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Myelodysplastic Syndromes 5Multiple Myeloma 5Mesothelioma, Malignant 5

Interventions

Pemetrexed 2Carboplatin 2tepotinib 1pembrolizumab 1patritumab deruxtecan 1lazertinib 1durvalumab 1atezolizumab 1Taxes 1Nivolumab 1Ipilimumab 1Cisplatin 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non-Small Cell Lung Cancer Metastatic × Ipilimumab × 1 year × Clear all
NCT03469960 2025-11-18

DICIPLE

Intergroupe Francophone de Cancerologie Thoracique

Phase 3 Completed
265 enrolled
Thoracic

Non-Small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡